Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sitaxsentan in Cardiac Surgery Subjects (FCAD02)
NCT00838383Phase 2Completed
- Sponsor
- Pfizer
- Start
- Aug 2006
- Primary completion
- Mar 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of sitaxsentan in pulmonary hypertension (PH), sponsored by Pfizer. Primary endpoints: Percent Change From 0 Hour in Pulmonary Vascular Resistance at 0.5 Hour Post-separation From CPB and Percent Change From 0 Hour in Pulmonary Vascular Resistance at 6 Hour Post-separation From CPB. Started Aug 2006; status: completed.
02
Drugs
sitaxsentan
03
Conditions
pulmonary hypertension (PH)
Beyond the preview
Go deeper on NCT00838383.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00838383.